We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+15.28%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.5B
AUM Growth
+$440M
(+41%)
Cap. Flow
+$272M
Cap. Flow
% of AUM
18.08%
Top 10 Holdings %
Top 10 Hldgs %
53.02%
Holding
49
New
11
Increased
14
Reduced
6
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$51.4M |
| 2 |
MDCO
Medicines Co
MDCO
|
+$32.7M |
| 3 |
Boston Scientific
BSX
|
+$32M |
| 4 |
KND
Kindred Healthcare
KND
|
+$29.7M |
| 5 |
GSK
GSK
|
+$24.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$44.9M |
| 2 |
Viatris
VTRS
|
+$34.9M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$32.4M |
| 4 |
VOLC
VOLCANO CORPORATION COM STK
VOLC
|
+$30M |
| 5 |
Quest Diagnostics
DGX
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.48% |
| 2 | Consumer Discretionary | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GNMK
26
DELISTED
GenMark Diagnostics, Inc
GNMK
| $23.8M | 1.58% |
1,748,100
+840,000
| +93% | +$9.39M |
|
|
ALR
27
DELISTED
Alere Inc
ALR
| $19M | 1.26% |
+500,000
| New | +$19.3M |
|
|
CCRN
28
DELISTED
Cross Country Healthcare
CCRN
| $17.8M | 1.18% |
1,422,565
+422,565
| +42% | +$4.32M |
|
|
TRVN
29
DELISTED
Trevena, Inc.
TRVN
| $17.2M | 1.14% |
+4,592
| New | +$15.2M |
|
|
BIOL
30
DELISTED
Biolase, Inc.
BIOL
| $14.6M | 0.97% |
444
+227
| +105% | +$7.1M |
|
|
31
Quest Diagnostics
DGX
$25.9B
| $13.3M | 0.88% |
197,622
-302,378
| -60% | -$19.1M |
|
32
Novavax
NVAX
$1.22B
| $11.9M | 0.79% |
100,000
-137,500
| -58% | -$14.4M |
|
|
AMRN
33
Amarin Corp
AMRN
$298M
| $11.8M | 0.78% |
600,000
| – | – |
|
|
AFFX
34
DELISTED
Affymetrix Inc
AFFX
| $9.87M | 0.66% |
+1,000,000
| New | +$8.74M |
|
35
AngioDynamics
ANGO
$610M
| $6.93M | 0.46% |
364,630
| – | – |
|
|
CRDC
36
DELISTED
CARDICA INC COM NEW (DE)
CRDC
| $5.86M | 0.39% |
837,485
| – | – |
|
37
Gyre Therapeutics
GYRE
$648M
| $4.1M | 0.27% |
1,981
| – | – |
|
38
Protalix BioTherapeutics
PLX
$183M
| $3.68M | 0.24% |
200,000
| – | – |
|
|
EGRX
39
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.11M | 0.21% |
+200,400
| New | +$2.56M |
|
40
Inovio Pharmaceuticals
INO
$54M
| $2.29M | 0.15% |
20,833
| – | – |
|
|
BRLI
41
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $369K | 0.02% |
11,485
-532,239
| -98% | -$15.4M |
|
|
BIOL
42
CALL
DELISTED
Biolase, Inc.
BIOL
| $139K | 0.01% |
+147
| New | +$4.59M |
|
43
Geron
GERN
$860M
| – | – |
-3,440,045
| Closed | -$6.88M |
|
44
ICU Medical
ICUI
$4.21B
| – | – |
-277,583
| Closed | -$17.8M |
|
|
45
Vertex Pharmaceuticals
VRTX
$122B
| – | – |
-400,000
| Closed | -$44.9M |
|
|
OTIC
46
DELISTED
Otonomy, Inc.
OTIC
| – | – |
-573,000
| Closed | -$13.8M |
|
|
ACHN
47
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-3,250,000
| Closed | -$32.4M |
|
|
WCG
48
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-235,174
| Closed | -$14.2M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2014 Portfolio in Review
As of Q4 2014, Camber Capital Management held 49 positions worth $1.5B, up 41% from $1.06B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Camber Capital Management deployed $272M of net new capital in Q4 2014, opening 11 new positions and adding to 14 existing holdings. Its largest new stake was Labcorp: 582,000 shares worth $54M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary.
On the sell side, the largest reduction was Viatris, an estimated $34.9M trimmed.
- Camber Capital Management's largest Q4 2014 buy was Labcorp: 582,000 shares worth $54M.
- Camber Capital Management added most to GSK in Q4 2014, an estimated $24.6M increase.
- Camber Capital Management's biggest Q4 2014 reduction was Viatris, cutting an estimated $34.9M.
- Camber Capital Management fully exited Vertex Pharmaceuticals in Q4 2014, selling an estimated $44.9M.
- Camber Capital Management's ten largest holdings make up 53% of its $1.5B portfolio in Q4 2014.
- Camber Capital Management opened 11 new positions and closed 6 in Q4 2014.
- Camber Capital Management's portfolio value rose 41% quarter-over-quarter to $1.5B.
Based on Camber Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.